PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alterity Therapeutics Limited (ATHE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US02155X1063

CUSIP

02155X106

Sector

Healthcare

IPO Date

Sep 5, 2002

Highlights

Market Cap

$42.64M

EPS (TTM)

-$6.99

Total Revenue (TTM)

$2.81M

Gross Profit (TTM)

$2.70M

EBITDA (TTM)

-$18.84M

Year Range

$1.00 - $5.87

Target Price

$11.00

Short %

6.38%

Short Ratio

0.46

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alterity Therapeutics Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%0.00%50.00%100.00%150.00%200.00%250.00%300.00%SeptemberOctoberNovemberDecember2025February
210.53%
10.29%
ATHE (Alterity Therapeutics Limited)
Benchmark (^GSPC)

Returns By Period

Alterity Therapeutics Limited had a return of 20.54% year-to-date (YTD) and 96.55% in the last 12 months. Over the past 10 years, Alterity Therapeutics Limited had an annualized return of -24.67%, while the S&P 500 had an annualized return of 11.31%, indicating that Alterity Therapeutics Limited did not perform as well as the benchmark.


ATHE

YTD

20.54%

1M

16.67%

6M

195.56%

1Y

96.55%

5Y*

-11.48%

10Y*

-24.67%

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ATHE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202545.02%20.54%
2024-15.26%-11.37%10.70%1.21%-10.74%-3.21%-11.61%-6.87%-11.91%-12.38%22.61%134.75%32.93%
202312.29%-17.90%-13.51%0.85%3.93%-4.05%3.86%-6.21%-8.82%-5.98%-22.38%37.57%-28.49%
202230.60%-9.60%-2.47%-11.09%-9.10%-8.78%-1.34%-7.11%-21.42%-10.72%-7.76%-3.92%-51.64%
202123.13%-3.03%-10.00%0.69%-7.59%-2.99%-0.77%5.43%-6.62%-3.94%-20.49%-25.77%-46.27%
20201.28%-24.05%-0.00%16.38%-16.94%105.17%22.69%60.96%-14.04%-38.61%22.58%-11.84%71.79%
201925.00%0.63%16.77%-8.51%-23.84%0.00%-22.90%10.89%1.78%1.76%-20.69%-15.22%-39.06%
2018-16.67%2.69%-20.22%-9.39%7.31%-8.79%6.93%2.72%-3.13%-7.47%-10.48%-23.13%-58.97%
201753.99%-12.75%42.93%1.60%-33.96%9.05%22.27%-4.64%4.87%9.29%6.86%-4.59%91.41%
2016-26.80%13.21%-21.11%29.23%3.27%25.11%-2.99%14.33%-14.05%-34.73%-16.27%-34.01%-62.48%
2015-6.10%-27.92%0.90%4.46%17.09%-14.60%0.85%-20.42%-4.15%-4.44%13.97%-26.13%-55.85%
201465.48%-2.50%-75.24%-36.79%9.04%17.36%-3.31%2.28%-4.46%-14.02%-11.96%1.23%-76.60%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 76, ATHE is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ATHE is 7676
Overall Rank
The Sharpe Ratio Rank of ATHE is 7474
Sharpe Ratio Rank
The Sortino Ratio Rank of ATHE is 8282
Sortino Ratio Rank
The Omega Ratio Rank of ATHE is 7878
Omega Ratio Rank
The Calmar Ratio Rank of ATHE is 7878
Calmar Ratio Rank
The Martin Ratio Rank of ATHE is 6969
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alterity Therapeutics Limited (ATHE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ATHE, currently valued at 0.89, compared to the broader market-2.000.002.000.891.74
The chart of Sortino ratio for ATHE, currently valued at 2.17, compared to the broader market-4.00-2.000.002.004.006.002.172.35
The chart of Omega ratio for ATHE, currently valued at 1.26, compared to the broader market0.501.001.502.001.261.32
The chart of Calmar ratio for ATHE, currently valued at 0.99, compared to the broader market0.002.004.006.000.992.61
The chart of Martin ratio for ATHE, currently valued at 2.48, compared to the broader market0.0010.0020.0030.002.4810.66
ATHE
^GSPC

The current Alterity Therapeutics Limited Sharpe ratio is 0.89. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alterity Therapeutics Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
0.89
1.74
ATHE (Alterity Therapeutics Limited)
Benchmark (^GSPC)

Dividends

Dividend History


Alterity Therapeutics Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-99.48%
0
ATHE (Alterity Therapeutics Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alterity Therapeutics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alterity Therapeutics Limited was 99.86%, occurring on Nov 20, 2024. The portfolio has not yet recovered.

The current Alterity Therapeutics Limited drawdown is 99.48%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.86%Sep 18, 20025433Nov 20, 2024
-2.17%Sep 9, 20022Sep 11, 20021Sep 12, 20023

Volatility

Volatility Chart

The current Alterity Therapeutics Limited volatility is 52.45%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
52.45%
3.07%
ATHE (Alterity Therapeutics Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alterity Therapeutics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Alterity Therapeutics Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab